ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

hyaluronidase (human recombinant)

Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.

Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 202457 company-led studies, 14 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenxits history only2211 open or runningphase 4since Oct 7, 2024Feb 20, 2020Mar 2027phase 2 · NCT06655155
Halozyme Therapeuticsits history only200 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Takeda60 open or runningphase 3since Dec 23, 2008Oct 29, 2008none ahead
Hoffmann-La Rocheits history only42 open or runningphase 2since Sep 11, 2017Sep 11, 2017Aug 31, 2029phase 2 · NCT07503340
Baxter Healthcareits history only30 open or runningphase 4since Dec 10, 2008Dec 10, 2008none ahead
Fosun Pharmaits history only11 open or runningphase 1since Feb 24, 2026Feb 24, 2026none ahead
Johnson & Johnsonits history only10 open or runningphase 1since Aug 6, 2015Aug 6, 2015none ahead

Also a collaborator on its studies: BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2008First study: phase 2 study in Primary Immunodeficiency DiseasesFirst studyNCT00782106 · 11 enrolled · United States
  2. Dec 23, 2008Phase 3 study in Primary Immunodeficiency DiseasesNCT00814320 · 89 enrolled · United States, Canada
  3. Aug 3, 2010Phase 3 study in Primary Immunodeficiency DiseasesNCT01175213 · 66 enrolled · United States
  4. Aug 25, 2011Phase 2 study in Angioedemas, HereditaryNCT01426763 · 12 enrolled · United States
  5. Dec 2, 2011Phase 3 study in Primary Immunodeficiency DiseasesNCT01485796 · 54 enrolled · United States
  6. Jun 29, 2012Phase 2 study in Angioedemas, HereditaryNCT01756157 · 47 enrolled · United States, Germany, Spain and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01756157Angioedemas, Hereditary · United States, Germany, Spain and more2CompletedSep 13, 201347
NCT01485796Primary Immunodeficiency Diseases · United States3CompletedJan 1, 201354
NCT01426763Angioedemas, Hereditary · United States2CompletedNov 28, 201112
NCT01175213Primary Immunodeficiency Diseases · United States3CompletedAug 6, 201366
NCT00814320Primary Immunodeficiency Diseases · United States, Canada3CompletedNov 11, 201089
NCT00782106Primary Immunodeficiency Diseases · United States2CompletedNov 1, 200711

How it is read

Names in the registry

  • “Efgartigimod PH20 SC”, 12 entries
  • “efgartigimod PH20 SC”, 10 entries
  • “rHuPH20”, 5 entries
  • “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
  • “recombinant human hyaluronidase”, 3 entries

Codes read as this program: RHUPH20.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.